Phoenix Biotechnology, Inc. (PBI)'s Focus
While the prevention and treatment of human malignant disease remains PBI's primary focus, novel, patented extracts of Nerium oleander continue to reveal promising avenues of research showing activity against certain viral and neurodegenerative diseases.
2011 and 2009 ASCO
"Poster Discussion Group"
2009 SIO Intl' Conference
"Best of SIO"
"Technology Super Star"
Glioblastoma research. In two independent labs, research has now established significant benefit of PBI-05204 against human glioblastoma (GBM) in mice with xenograft tumors. The response to PBI-05204 alone when administered orally was significant, but the response when PBI-05204 was used in combination with temozolamide and radiotherapy was outstanding. Mechanistic and related pharmacology studies are currently underway.
Neurodegenerative research. Ongoing research has now demonstrated that PBI-05204 reduces oxidative damage and neuronal cell death as well as neuroinflammation. The work, conducted at The University of Texas at San Antonio, showed that PBI’s lead drug reduced the expression of pro-inflammatory cytokines. The data clearly shows that PBI-05204 reduces neuroinflammatory reactions in microglial cells and suggest its therapeutic potential for the treatment of Alzheimer’s disease. In vivo studies are currently underway.
A research program with Dr. Claudio Festuccia (Department of Experimental Medicine, University of L’Quila, Italy) is currently underway exploring the relative effects of PBI’s oleander extract combined with radiotherapy against glioblastoma.